Company Profiles

driven by the PitchBook Platform

Longevity Biotech

Longevity Biotech
2010 FOUNDED
PRIVATE STATUS
Grant LATEST DEAL TYPE
4 INVESTORS
Description

Provider of a new class of therapeutics designed to deliver clinically transformative products that tackle challenging aspects of medicine today. The company's Hybridtides are synthetic peptides that provides critical enhancements over previous peptide development efforts, enabling the development of therapeutic peptidomimetics that have a longer half-life compared to currently approved peptide drugs.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 3624 Market Street
  • Suite 300
  • Philadelphia, PA 19104
  • United States

+1 (215) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Longevity Biotech’s full profile, request a free trial.

Longevity Biotech Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 27-Oct-2017 00000 Completed Pre-Clinical Trials
3. Seed Round 00000 Completed Pre-Clinical Trials
2. Grant 19-Apr-2012 $350K $170K Completed Startup
1. Debt - General 12-Apr-2011 $170K $170K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Longevity Biotech Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Michael J. Fox Foundation Limited Partner 000 0000 000000 0
National Multiple Sclerosis Society (NMSS) Other 000 0000 000000 0
Breakout Labs Not-For-Profit Venture Capital Minority 000 0000 000000 0
NetScientific Venture Capital Minority 000 0000 000000 0

Longevity Biotech Executive Team (3)

Name Title Board
Seat
Contact
Info
Scott Shandler Ph.D Co-Founder & Chief Executive Officer
Samuel Gellman Ph.D Co-Founder & Head, Peptide Chemistry
Uma Sinha Ph.D Executive Vice President, Preclinical Development